These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Evaluation and recommendations on good clinical laboratory practice guidelines for phase I-III clinical trials. Sarzotti-Kelsoe M; Cox J; Cleland N; Denny T; Hural J; Needham L; Ozaki D; Rodriguez-Chavez IR; Stevens G; Stiles T; Tarragona-Fiol T; Simkins A PLoS Med; 2009 May; 6(5):e1000067. PubMed ID: 19536325 [TBL] [Abstract][Full Text] [Related]
6. Statistical and ethical issues in the design and conduct of phase I and II clinical trials of new anticancer agents. Ratain MJ; Mick R; Schilsky RL; Siegler M J Natl Cancer Inst; 1993 Oct; 85(20):1637-43. PubMed ID: 8411243 [No Abstract] [Full Text] [Related]
7. Statistical shortcomings in licensing applications. Lewis JA; Facey KM Stat Med; 1998 Aug 15-30; 17(15-16):1663-73. PubMed ID: 9749438 [TBL] [Abstract][Full Text] [Related]
8. Examining heterogeneity in phase II trial designs may improve success in phase III. Tuma RS J Natl Cancer Inst; 2008 Feb; 100(3):164-6. PubMed ID: 18230788 [No Abstract] [Full Text] [Related]
10. Standardization, more funds on horizon for clinical trials. McNeil C J Natl Cancer Inst; 2005 Apr; 97(8):555-7. PubMed ID: 15840874 [No Abstract] [Full Text] [Related]
11. Correlation of single arm versus randomised phase 2 oncology trial characteristics with phase 3 outcome. Monzon JG; Hay AE; McDonald GT; Pater JL; Meyer RM; Chen E; Chen BE; Dancey JE Eur J Cancer; 2015 Nov; 51(17):2501-7. PubMed ID: 26338195 [TBL] [Abstract][Full Text] [Related]
12. Randomized phase II trials: a long-term investment with promising returns. Sharma MR; Stadler WM; Ratain MJ J Natl Cancer Inst; 2011 Jul; 103(14):1093-100. PubMed ID: 21709274 [TBL] [Abstract][Full Text] [Related]
13. What was wrong and might now go right with clinical trials for lupus? Merrill JT Curr Rheumatol Rep; 2009 Aug; 11(4):235-7. PubMed ID: 19691925 [No Abstract] [Full Text] [Related]
14. Designing randomised trials: both large and small trials are needed. Stenning SP; Parmar MK Ann Oncol; 2002; 13 Suppl 4():131-8. PubMed ID: 12401679 [No Abstract] [Full Text] [Related]
15. [Continual reassessment method (CRM)]. Ishizuka N Gan To Kagaku Ryoho; 2000 Aug; 27(9):1449-57. PubMed ID: 10969605 [TBL] [Abstract][Full Text] [Related]
17. Missing data from mesothelioma study. Aelony Y J Thorac Cardiovasc Surg; 2003 Feb; 125(2):442-3. PubMed ID: 12579130 [No Abstract] [Full Text] [Related]
18. Phase III trials of targeted anticancer therapies: redesigning the concept. Ocana A; Amir E; Vera-Badillo F; Seruga B; Tannock IF Clin Cancer Res; 2013 Sep; 19(18):4931-40. PubMed ID: 23881926 [TBL] [Abstract][Full Text] [Related]
19. The phase II/III transition. Toward the proof of efficacy in cancer clinical trials. Fazzari M; Heller G; Scher HI Control Clin Trials; 2000 Aug; 21(4):360-8. PubMed ID: 10913810 [TBL] [Abstract][Full Text] [Related]
20. Design of oncology clinical trials: a review. Ananthakrishnan R; Menon S Crit Rev Oncol Hematol; 2013 Oct; 88(1):144-53. PubMed ID: 23623356 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]